ABC:LSE-Abcam plc (GBX)

COMMON STOCK | Biotechnology | LSE

Last Closing Price

GBX 1,408.00

Change

0.00 (0.00)%

Market Cap

GBX 3.19B

Volume

0.14M

Average Target Price

GBX 1,383.33 (-1.75%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Abcam plc also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. The company was founded in 1998 and is headquartered in Cambridge, the United Kingdom. Address: Discovery Drive, Cambridge, United Kingdom, CB2 0AX

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HCM:LSE Hutchison China MediTech Limit..

N/A

GBX3.33B 17.41 N/A
GNS:LSE Genus plc

N/A

GBX2.71B 66.98 28.32
PRTC:LSE PureTech Health plc

N/A

GBX0.83B 1.82 0.95
OXB:LSE Oxford Biomedica plc

N/A

GBX0.71B N/A 615.00
ERGO:LSE Ergomed plc

N/A

GBX0.42B 68.32 33.73
SLN:LSE Silence Therapeutics plc

N/A

GBX0.35B N/A N/A
AVCT:LSE Avacta Group Plc

N/A

GBX0.30B N/A N/A
VRP:LSE Verona Pharma plc

N/A

GBX0.23B N/A N/A
BVXP:LSE Bioventix PLC

N/A

GBX0.21B 29.01 24.68
ARIX:LSE Arix Bioscience plc

N/A

GBX0.20B 10.64 N/A

ETFs Containing ABC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.14% 30% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.14% 30% F 59% F
Trailing 12 Months  
Capital Gain 5.47% 28% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.47% 28% F 58% F
Trailing 5 Years  
Capital Gain 141.10% 80% B- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 141.10% 80% B- 89% B+
Average Annual (5 Year Horizon)  
Capital Gain 20.69% N/A N/A 83% B
Dividend Return 0.33% N/A N/A 30% F
Total Return 21.02% N/A N/A 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 20.48% N/A N/A 49% F
Risk Adjusted Return 102.62% N/A N/A 91% A-
Market Capitalization 3.19B 98% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 234.67 18% F 3% F
Price/Book Ratio 6.32 41% F 11% F
Price / Cash Flow Ratio 50.63 4% F 7% F
EV/EBITDA 80.93 18% F 5% F
Management Effectiveness  
Return on Equity 2.82% 83% B 57% F
Return on Invested Capital 2.94% 80% B- 49% F
Return on Assets 4.42% 91% A- 74% C
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.54 73% C 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector